EVOTEC SE: TRANSLATIONAL BRIDGE beLAB2122 IN COLLABORATION WITH BRISTOL MYERS SQUIBB IDENTIFIES FIRST PROJECT
Hamburg, Germany, 27 October 2021:
- FIRST PROJECT ORIGINATES FROM THE GERMAN CANCER RESEARCH CENTER (“DKFZ”) AND HEIDELBERG UNIVERSITY IN HEIDELBERG
- beLAB2122 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. After signing the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic BRIDGE collaboration has now been nominated.